PLoS Pathogens (Sep 2021)

Teaching a new mouse old tricks: Humanized mice as an infection model for Variola virus.

  • Christina L Hutson,
  • Ashley V Kondas,
  • Jana M Ritter,
  • Zachary Reed,
  • Sharon Dietz Ostergaard,
  • Clint N Morgan,
  • Nadia Gallardo-Romero,
  • Cassandra Tansey,
  • Matthew R Mauldin,
  • Johanna S Salzer,
  • Christine M Hughes,
  • Cynthia S Goldsmith,
  • Darin Carroll,
  • Victoria A Olson

DOI
https://doi.org/10.1371/journal.ppat.1009633
Journal volume & issue
Vol. 17, no. 9
p. e1009633

Abstract

Read online

Smallpox, caused by the solely human pathogen Variola virus (VARV), was declared eradicated in 1980. While known VARV stocks are secure, smallpox remains a bioterrorist threat agent. Recent U.S. Food and Drug Administration approval of the first smallpox anti-viral (tecovirimat) therapeutic was a successful step forward in smallpox preparedness; however, orthopoxviruses can become resistant to treatment, suggesting a multi-therapeutic approach is necessary. Animal models are required for testing medical countermeasures (MCMs) and ideally MCMs are tested directly against the pathogen of interest. Since VARV only infects humans, a representative animal model for testing therapeutics directly against VARV remains a challenge. Here we show that three different humanized mice strains are highly susceptible to VARV infection, establishing the first small animal model using VARV. In comparison, the non-humanized, immunosuppressed background mouse was not susceptible to systemic VARV infection. Following an intranasal VARV challenge that mimics the natural route for human smallpox transmission, the virus spread systemically within the humanized mouse before mortality (~ 13 days post infection), similar to the time from exposure to symptom onset for ordinary human smallpox. Our identification of a permissive/representative VARV animal model can facilitate testing of MCMs in a manner consistent with their intended use.